Immunohistochemistry of CD8+ T-cells of HCC biopsy in 24 patients before treatment with atezolizumab plus bevacizumab demonstrated that higher CD8+ T-cells are associated with better progression-free survival. The gene discussed is CD8A; the disease is hepatocellular carcinoma.